I-Mab (IMAB) Competitors

I-Mab (NASDAQ:IMAB) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.

Does the media favor IMAB or DBVT?

In the previous week, I-Mab had 2 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for I-Mab and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.94 beat I-Mab's score of 0.77 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor IMAB or DBVT?

DBV Technologies received 345 more outperform votes than I-Mab when rated by MarketBeat users. However, 65.26% of users gave I-Mab an outperform vote while only 54.12% of users gave DBV Technologies an outperform vote.

Company	Underperform	Outperform
I-Mab	Outperform Votes 62 65.26%	Underperform Votes 33 34.74%
DBV Technologies	Outperform Votes 407 54.12%	Underperform Votes 345 45.88%

Is IMAB or DBVT more profitable?

I-Mab has a net margin of 0.00% compared to DBV Technologies' net margin of -815.73%. I-Mab's return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
DBV Technologies	-815.73%	-106.07%	-76.17%

Which has higher valuation and earnings, IMAB or DBVT?

DBV Technologies has higher revenue and earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.27M	22.75	-$206.44M	N/A	N/A
DBV Technologies	$15.73M	16.72	-$72.73M	-$4.92	-1.95

Which has more risk & volatility, IMAB or DBVT?

I-Mab has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.66, meaning that its share price is 166% less volatile than the S&P 500.

Do analysts rate IMAB or DBVT?

I-Mab currently has a consensus price target of $5.50, indicating a potential upside of 502.01%. DBV Technologies has a consensus price target of $15.50, indicating a potential upside of 61.46%. Given I-Mab's stronger consensus rating and higher probable upside, equities research analysts clearly believe I-Mab is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
DBV Technologies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of IMAB or DBVT?

38.4% of I-Mab shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 1.9% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

I-Mab beats DBV Technologies on 11 of the 16 factors compared between the two stocks.